Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Part of paid clinical trials in Buffalo, New York.

Sponsor
Allogene Therapeutics
Study ID
NCT06925685
Status
Enrolling By Invitation

Conditions

  • Hematologic Malignancies
  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product.

Key Dates

Start date
Jan 31, 2025
Status verified
Apr 2025
Primary completion
Jan 31, 2039
Completion
Jan 31, 2039

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

Incidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEs [ Time Frame: Up to 15 years post treatment with allogeneic CAR T-cell product ]

Locations (1)

FacilityCityStateZIPSite coordinators
Circuit ClinicalBuffaloNew York14203-

Find similar trials in Buffalo, NY

By research site
Circuit Clinical· Buffalo, NY

Related Studies